{
  "DOI": "10.1038/ejhg.2016.114",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/ejhg.2016.114",
  "alternative-id": [
    "BFejhg2016114"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "4 March 2016"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "20 July 2016"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "22 July 2016"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "31 August 2016"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "The authors declare no conflict of interest."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Kapoor",
      "given": "Ritika",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Tan-Koi",
      "given": "Wei Chuen",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Teo",
      "given": "Yik-Ying",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2016,
        8,
        31
      ]
    ],
    "date-time": "2016-08-31T18:03:23Z",
    "timestamp": 1472666603000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ],
    "date-time": "2023-05-18T17:16:01Z",
    "timestamp": 1684430161000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        3
      ]
    ],
    "date-time": "2024-04-03T09:56:58Z",
    "timestamp": 1712138218126
  },
  "is-referenced-by-count": 27,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "12",
  "issued": {
    "date-parts": [
      [
        2016,
        8,
        31
      ]
    ]
  },
  "journal-issue": {
    "issue": "12",
    "published-print": {
      "date-parts": [
        [
          2016,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "http://www.springer.com/tdm",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2016,
            8,
            31
          ]
        ],
        "date-time": "2016-08-31T00:00:00Z",
        "timestamp": 1472601600000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/ejhg2016114.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/ejhg2016114",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/ejhg2016114.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1651-1657",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2016,
        8,
        31
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2016,
        8,
        31
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2016,
        12
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1038/35057062",
      "author": "ES Lander",
      "doi-asserted-by": "publisher",
      "first-page": "860",
      "journal-title": "Nature",
      "key": "BFejhg2016114_CR1",
      "unstructured": "Lander ES, Linton LM, Birren B et al: Initial sequencing and analysis of the human genome. Nature 2001; 409: 860–921.",
      "volume": "409",
      "year": "2001"
    },
    {
      "DOI": "10.1126/science.1058040",
      "author": "JC Venter",
      "doi-asserted-by": "publisher",
      "first-page": "1304",
      "journal-title": "Science",
      "key": "BFejhg2016114_CR2",
      "unstructured": "Venter JC, Adams MD, Myers EW et al: The sequence of the human genome. Science 2001; 291: 1304–1351.",
      "volume": "291",
      "year": "2001"
    },
    {
      "DOI": "10.1001/jama.285.5.540",
      "author": "FS Collins",
      "doi-asserted-by": "publisher",
      "first-page": "540",
      "journal-title": "JAMA",
      "key": "BFejhg2016114_CR3",
      "unstructured": "Collins FS, McKusick VA : Implications of the Human Genome Project for medical science. JAMA 2001; 285: 540–544.",
      "volume": "285",
      "year": "2001"
    },
    {
      "DOI": "10.2105/AJPH.2003.026708",
      "author": "RP Ojha",
      "doi-asserted-by": "publisher",
      "first-page": "385",
      "journal-title": "Am J Public Health",
      "key": "BFejhg2016114_CR4",
      "unstructured": "Ojha RP, Thertulien R : Health care policy issues as a result of the genetic revolution: implications for public health. Am J Public Health 2005; 95: 385–388.",
      "volume": "95",
      "year": "2005"
    },
    {
      "DOI": "10.1056/NEJMoa0809329",
      "author": "TE Klein",
      "doi-asserted-by": "publisher",
      "first-page": "753",
      "journal-title": "N Engl J Med",
      "key": "BFejhg2016114_CR5",
      "unstructured": "Klein TE, Altman RB, Eriksson N et al: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753–764.",
      "volume": "360",
      "year": "2009"
    },
    {
      "DOI": "10.1056/NEJMoa0708078",
      "author": "UI Schwarz",
      "doi-asserted-by": "publisher",
      "first-page": "999",
      "journal-title": "N Engl J Med",
      "key": "BFejhg2016114_CR6",
      "unstructured": "Schwarz UI, Ritchie MD, Bradford Y et al: Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999–1008.",
      "volume": "358",
      "year": "2008"
    },
    {
      "DOI": "10.1016/S0140-6736(02)07873-X",
      "author": "S Mallal",
      "doi-asserted-by": "publisher",
      "first-page": "727",
      "journal-title": "Lancet",
      "key": "BFejhg2016114_CR7",
      "unstructured": "Mallal S, Nolan D, Witt C et al: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727–732.",
      "volume": "359",
      "year": "2002"
    },
    {
      "DOI": "10.1056/NEJMoa0706135",
      "author": "S Mallal",
      "doi-asserted-by": "publisher",
      "first-page": "568",
      "journal-title": "N Engl J Med",
      "key": "BFejhg2016114_CR8",
      "unstructured": "Mallal S, Phillips E, Carosi G et al: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.",
      "volume": "358",
      "year": "2008"
    },
    {
      "DOI": "10.1038/428486a",
      "author": "WH Chung",
      "doi-asserted-by": "publisher",
      "first-page": "486",
      "journal-title": "Nature",
      "key": "BFejhg2016114_CR9",
      "unstructured": "Chung WH, Hung SI, Hong HS et al: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.",
      "volume": "428",
      "year": "2004"
    },
    {
      "DOI": "10.2217/pgs.09.162",
      "author": "SI Hung",
      "doi-asserted-by": "publisher",
      "first-page": "349",
      "journal-title": "Pharmacogenomics",
      "key": "BFejhg2016114_CR10",
      "unstructured": "Hung SI, Chung WH, Liu ZS et al: Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11: 349–356.",
      "volume": "11",
      "year": "2010"
    },
    {
      "DOI": "10.1073/pnas.0409500102",
      "author": "SI Hung",
      "doi-asserted-by": "publisher",
      "first-page": "4134",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "BFejhg2016114_CR11",
      "unstructured": "Hung SI, Chung WH, Liou LB et al: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134–4139.",
      "volume": "102",
      "year": "2005"
    },
    {
      "DOI": "10.1186/1471-2350-12-118",
      "author": "R Somkrua",
      "doi-asserted-by": "publisher",
      "first-page": "118",
      "journal-title": "BMC Med Genet",
      "key": "BFejhg2016114_CR12",
      "unstructured": "Somkrua R, Eickman EE, Saokaew S et al: Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011; 12: 118.",
      "volume": "12",
      "year": "2011"
    },
    {
      "author": "Y Ando",
      "first-page": "6921",
      "journal-title": "Cancer Res",
      "key": "BFejhg2016114_CR13",
      "unstructured": "Ando Y, Saka H, Ando M et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921–6926.",
      "volume": "60",
      "year": "2000"
    },
    {
      "DOI": "10.1200/JCO.2004.07.173",
      "author": "F Innocenti",
      "doi-asserted-by": "publisher",
      "first-page": "1382",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg2016114_CR14",
      "unstructured": "Innocenti F, Undevia SD, Iyer L et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382–1388.",
      "volume": "22",
      "year": "2004"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-03-0548",
      "author": "E Rouits",
      "doi-asserted-by": "publisher",
      "first-page": "5151",
      "journal-title": "Clin Cancer Res",
      "key": "BFejhg2016114_CR15",
      "unstructured": "Rouits E, Boisdron-Celle M, Dumont A et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151–5159.",
      "volume": "10",
      "year": "2004"
    },
    {
      "DOI": "10.1016/S0140-6736(06)69255-6",
      "author": "G Koren",
      "doi-asserted-by": "publisher",
      "first-page": "704",
      "journal-title": "Lancet",
      "key": "BFejhg2016114_CR16",
      "unstructured": "Koren G, Cairns J, Chitayat D et al: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704.",
      "volume": "368",
      "year": "2006"
    },
    {
      "DOI": "10.1097/FPC.0000000000000106",
      "author": "DS Lehmann",
      "doi-asserted-by": "publisher",
      "first-page": "51",
      "journal-title": "Pharmacogenet Genomics",
      "key": "BFejhg2016114_CR17",
      "unstructured": "Lehmann DS, Ribaudo HJ, Daar ES et al: Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 2015; 25: 51–59.",
      "volume": "25",
      "year": "2015"
    },
    {
      "DOI": "10.1016/S0140-6736(10)60452-7",
      "author": "EA Ashley",
      "doi-asserted-by": "publisher",
      "first-page": "1525",
      "journal-title": "Lancet",
      "key": "BFejhg2016114_CR18",
      "unstructured": "Ashley EA, Butte AJ, Wheeler MT et al: Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525–1535.",
      "volume": "375",
      "year": "2010"
    },
    {
      "DOI": "10.1039/C6MB00115G",
      "author": "B Rabbani",
      "doi-asserted-by": "publisher",
      "first-page": "1818",
      "journal-title": "Mol Biosyst",
      "key": "BFejhg2016114_CR19",
      "unstructured": "Rabbani B, Nakaoka H, Akhondzadeh S et al: Next generation sequencing: implications in personalized medicine and pharmacogenomics. Mol Biosyst 2016; 12: 1818–1830.",
      "volume": "12",
      "year": "2016"
    },
    {
      "DOI": "10.1093/nar/gkt1229",
      "author": "D Welter",
      "doi-asserted-by": "publisher",
      "first-page": "D1001",
      "journal-title": "Nucleic Acids Res",
      "key": "BFejhg2016114_CR20",
      "unstructured": "Welter D, MacArthur J, Morales J et al: The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014; 42: D1001–D1006.",
      "volume": "42",
      "year": "2014"
    },
    {
      "DOI": "10.1038/clpt.2012.96",
      "author": "M Whirl-Carrillo",
      "doi-asserted-by": "publisher",
      "first-page": "414",
      "journal-title": "Clin Pharmacol Therap",
      "key": "BFejhg2016114_CR21",
      "unstructured": "Whirl-Carrillo M, McDonagh EM, Hebert JM et al: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Therap 2012; 92: 414–417.",
      "volume": "92",
      "year": "2012"
    },
    {
      "DOI": "10.1038/tpj.2011.7",
      "author": "SL Chan",
      "doi-asserted-by": "publisher",
      "first-page": "312",
      "journal-title": "Pharmacogenomics J",
      "key": "BFejhg2016114_CR22",
      "unstructured": "Chan SL, Suo C, Lee SC et al: Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J 2012; 12: 312–318.",
      "volume": "12",
      "year": "2012"
    },
    {
      "DOI": "10.1182/blood-2008-01-134247",
      "author": "GM Cooper",
      "doi-asserted-by": "publisher",
      "first-page": "1022",
      "journal-title": "Blood",
      "key": "BFejhg2016114_CR23",
      "unstructured": "Cooper GM, Johnson JA, Langaee TY et al: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022–1027.",
      "volume": "112",
      "year": "2008"
    },
    {
      "DOI": "10.2217/pgs.10.95",
      "author": "S Marsh",
      "doi-asserted-by": "publisher",
      "first-page": "1003",
      "journal-title": "Pharmacogenomics",
      "key": "BFejhg2016114_CR24",
      "unstructured": "Marsh S, Hoskins JM : Irinotecan pharmacogenomics. Pharmacogenomics 2010; 11: 1003–1010.",
      "volume": "11",
      "year": "2010"
    },
    {
      "DOI": "10.1038/sj.tpj.6500072",
      "author": "L Iyer",
      "doi-asserted-by": "publisher",
      "first-page": "43",
      "journal-title": "Pharmacogenomics J",
      "key": "BFejhg2016114_CR25",
      "unstructured": "Iyer L, Das S, Janisch L et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43–47.",
      "volume": "2",
      "year": "2002"
    },
    {
      "DOI": "10.1093/jnci/djm115",
      "author": "JM Hoskins",
      "doi-asserted-by": "publisher",
      "first-page": "1290",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg2016114_CR26",
      "unstructured": "Hoskins JM, Goldberg RM, Qu P et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290–1295.",
      "volume": "99",
      "year": "2007"
    },
    {
      "DOI": "10.2217/PGS.15.93",
      "author": "JT Brown",
      "doi-asserted-by": "publisher",
      "first-page": "1513",
      "journal-title": "Pharmacogenomics",
      "key": "BFejhg2016114_CR27",
      "unstructured": "Brown JT, Bishop JR : Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics 2015; 16: 1513–1520.",
      "volume": "16",
      "year": "2015"
    },
    {
      "DOI": "10.1097/01.chi.0000246056.83791.b6",
      "author": "D Michelson",
      "doi-asserted-by": "publisher",
      "first-page": "242",
      "journal-title": "J Am Acad Child Adolesc Psychiatry",
      "key": "BFejhg2016114_CR28",
      "unstructured": "Michelson D, Read HA, Ruff DD et al: CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46: 242–251.",
      "volume": "46",
      "year": "2007"
    },
    {
      "DOI": "10.4103/0976-500X.120957",
      "author": "J Sultana",
      "doi-asserted-by": "publisher",
      "first-page": "S73",
      "journal-title": "J Pharmacol Pharmacother",
      "key": "BFejhg2016114_CR29",
      "unstructured": "Sultana J, Cutroneo P, Trifiro G : Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 2013; 4: S73–S77.",
      "volume": "4",
      "year": "2013"
    },
    {
      "DOI": "10.1086/504874",
      "author": "A Rauch",
      "doi-asserted-by": "publisher",
      "first-page": "99",
      "journal-title": "Clin Infect Dis",
      "key": "BFejhg2016114_CR30",
      "unstructured": "Rauch A, Nolan D, Martin A et al: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99–102.",
      "volume": "43",
      "year": "2006"
    },
    {
      "key": "BFejhg2016114_CR31",
      "unstructured": "Whitney K: PREDICT helps pinpoint right statin for patient: Reporter: Vanderbilt University Medical Center: Nashville, TN, USA, 2012."
    },
    {
      "author": "L Moja",
      "first-page": "CD006243",
      "journal-title": "Cochrane Database Syst Rev",
      "key": "BFejhg2016114_CR32",
      "unstructured": "Moja L, Tagliabue L, Balduzzi S et al: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4: CD006243.",
      "volume": "4",
      "year": "2012"
    },
    {
      "DOI": "10.1212/WNL.0b013e31826aac73",
      "author": "D Dong",
      "doi-asserted-by": "publisher",
      "first-page": "1259",
      "journal-title": "Neurology",
      "key": "BFejhg2016114_CR33",
      "unstructured": "Dong D, Sung C, Finkelstein EA : Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259–1267.",
      "volume": "79",
      "year": "2012"
    },
    {
      "DOI": "10.1111/epi.12325",
      "author": "W Rattanavipapong",
      "doi-asserted-by": "publisher",
      "first-page": "1628",
      "journal-title": "Epilepsia",
      "key": "BFejhg2016114_CR34",
      "unstructured": "Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N et al: Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia 2013; 54: 1628–1638.",
      "volume": "54",
      "year": "2013"
    },
    {
      "DOI": "10.1007/s11096-013-9777-9",
      "author": "S Tiamkao",
      "doi-asserted-by": "publisher",
      "first-page": "608",
      "journal-title": "Int J Clin Pharm",
      "key": "BFejhg2016114_CR35",
      "unstructured": "Tiamkao S, Jitpimolmard J, Sawanyawisuth K et al: Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand. Int J Clin Pharm 2013; 35: 608–612.",
      "volume": "35",
      "year": "2013"
    },
    {
      "DOI": "10.1097/FPC.0000000000000107",
      "author": "R Kapoor",
      "doi-asserted-by": "publisher",
      "first-page": "60",
      "journal-title": "Pharmacogenet Genomics",
      "key": "BFejhg2016114_CR36",
      "unstructured": "Kapoor R, Martinez-Vega R, Dong D et al: Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenet Genomics 2015; 25: 60–72.",
      "volume": "25",
      "year": "2015"
    },
    {
      "DOI": "10.1086/595890",
      "author": "WB Park",
      "doi-asserted-by": "publisher",
      "first-page": "365",
      "journal-title": "Clin Infect Dis",
      "key": "BFejhg2016114_CR37",
      "unstructured": "Park WB, Choe PG, Song KH et al: Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009; 48: 365–367.",
      "volume": "48",
      "year": "2009"
    },
    {
      "DOI": "10.1097/QAD.0b013e3283103ce6",
      "author": "BR Schackman",
      "doi-asserted-by": "publisher",
      "first-page": "2025",
      "journal-title": "AIDS",
      "key": "BFejhg2016114_CR38",
      "unstructured": "Schackman BR, Scott CA, Walensky RP et al: The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22: 2025–2033.",
      "volume": "22",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.eimc.2009.09.010",
      "author": "D Nieves Calatrava",
      "doi-asserted-by": "publisher",
      "first-page": "590",
      "journal-title": "Enferm Infecc Microbiol Clin",
      "key": "BFejhg2016114_CR39",
      "unstructured": "Nieves Calatrava D, Calle-Martin Ode L, Iribarren-Loyarte JA et al: Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm Infecc Microbiol Clin 2010; 28: 590–595.",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1097/00008571-200406000-00002",
      "author": "DA Hughes",
      "doi-asserted-by": "publisher",
      "first-page": "335",
      "journal-title": "Pharmacogenetics",
      "key": "BFejhg2016114_CR40",
      "unstructured": "Hughes DA, Vilar FJ, Ward CC et al: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14: 335–342.",
      "volume": "14",
      "year": "2004"
    },
    {
      "DOI": "10.1002/mgg3.83",
      "author": "V Shotelersuk",
      "doi-asserted-by": "publisher",
      "first-page": "210",
      "journal-title": "Mol Genet Genomic Med",
      "key": "BFejhg2016114_CR41",
      "unstructured": "Shotelersuk V, Limwongse C, Mahasirimongkol S : Genetics and genomics in Thailand: challenges and opportunities. Mol Genet Genomic Med 2014; 2: 210–216.",
      "volume": "2",
      "year": "2014"
    },
    {
      "DOI": "10.1001/jama.2009.1232",
      "author": "AR Shuldiner",
      "doi-asserted-by": "publisher",
      "first-page": "849",
      "journal-title": "JAMA",
      "key": "BFejhg2016114_CR42",
      "unstructured": "Shuldiner AR, O'Connell JR, Bliden KP et al: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849–857.",
      "volume": "302",
      "year": "2009"
    },
    {
      "DOI": "10.1161/CIRCINTERVENTIONS.111.962142",
      "author": "G Pare",
      "doi-asserted-by": "publisher",
      "first-page": "514",
      "journal-title": "Circ Cardiovasc Interv",
      "key": "BFejhg2016114_CR43",
      "unstructured": "Pare G, Eikelboom JW, Sibbing D et al: Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2011; 4: 514–521, discussion 521.",
      "volume": "4",
      "year": "2011"
    },
    {
      "DOI": "10.1111/j.1538-7836.2011.04570.x",
      "author": "Y Li",
      "doi-asserted-by": "publisher",
      "first-page": "199",
      "journal-title": "J Thromb Haemost",
      "key": "BFejhg2016114_CR44",
      "unstructured": "Li Y, Tang HL, Hu YF et al: The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012; 10: 199–206.",
      "volume": "10",
      "year": "2012"
    },
    {
      "DOI": "10.2217/pgs.12.104",
      "author": "SL Chan",
      "doi-asserted-by": "publisher",
      "first-page": "1247",
      "journal-title": "Pharmacogenomics",
      "key": "BFejhg2016114_CR45",
      "unstructured": "Chan SL, Suo C, Chia KS et al: The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. Pharmacogenomics 2012; 13: 1247–1256.",
      "volume": "13",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.thromres.2006.10.021",
      "author": "T Yin",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Thromb Res",
      "key": "BFejhg2016114_CR46",
      "unstructured": "Yin T, Miyata T : Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 2007; 120: 1–10.",
      "volume": "120",
      "year": "2007"
    },
    {
      "DOI": "10.1101/gr.129668.111",
      "author": "LB Ramsey",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Genome Res",
      "key": "BFejhg2016114_CR47",
      "unstructured": "Ramsey LB, Bruun GH, Yang W et al: Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012; 22: 1–8.",
      "volume": "22",
      "year": "2012"
    },
    {
      "DOI": "10.1038/sj.tpj.6500046",
      "author": "LJ Lesko",
      "doi-asserted-by": "publisher",
      "first-page": "20",
      "journal-title": "Pharmacogenomics J",
      "key": "BFejhg2016114_CR48",
      "unstructured": "Lesko LJ, Woodcock J : Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002; 2: 20–24.",
      "volume": "2",
      "year": "2002"
    },
    {
      "DOI": "10.4103/0253-7613.43158",
      "author": "A Surendiran",
      "doi-asserted-by": "publisher",
      "first-page": "137",
      "journal-title": "Indian J Pharmacol",
      "key": "BFejhg2016114_CR49",
      "unstructured": "Surendiran A, Pradhan SC, Adithan C : Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol 2008; 40: 137–143.",
      "volume": "40",
      "year": "2008"
    },
    {
      "DOI": "10.1038/clpt.2014.97",
      "author": "MV Relling",
      "doi-asserted-by": "publisher",
      "first-page": "169",
      "journal-title": "Clin Pharmacol Ther",
      "key": "BFejhg2016114_CR50",
      "unstructured": "Relling MV, McDonagh EM, Chang T et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 2014; 96: 169–174.",
      "volume": "96",
      "year": "2014"
    },
    {
      "DOI": "10.2174/1389200215666140130124910",
      "author": "KE Caudle",
      "doi-asserted-by": "publisher",
      "first-page": "209",
      "journal-title": "Curr Drug Metab",
      "key": "BFejhg2016114_CR51",
      "unstructured": "Caudle KE, Klein TE, Hoffman JM et al: Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014; 15: 209–217.",
      "volume": "15",
      "year": "2014"
    },
    {
      "DOI": "10.1038/clpt.2010.279",
      "author": "MV Relling",
      "doi-asserted-by": "publisher",
      "first-page": "464",
      "journal-title": "Clin Pharmacol Ther",
      "key": "BFejhg2016114_CR52",
      "unstructured": "Relling MV, Klein TE : CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464–467.",
      "volume": "89",
      "year": "2011"
    },
    {
      "DOI": "10.1038/clpt.2011.34",
      "author": "JJ Swen",
      "doi-asserted-by": "publisher",
      "first-page": "662",
      "journal-title": "Clin Pharmacol Ther",
      "key": "BFejhg2016114_CR53",
      "unstructured": "Swen JJ, Nijenhuis M, de Boer A et al: Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 2011; 89: 662–673.",
      "volume": "89",
      "year": "2011"
    },
    {
      "DOI": "10.1056/NEJMoa1310669",
      "author": "SE Kimmel",
      "doi-asserted-by": "publisher",
      "first-page": "2283",
      "journal-title": "N Engl J Med",
      "key": "BFejhg2016114_CR54",
      "unstructured": "Kimmel SE, French B, Kasner SE et al: A pharmacogenetic versus a clinical algorithm for Warfarin Dosing. N Engl J Med 2013; 369: 2283–2293.",
      "volume": "369",
      "year": "2013"
    },
    {
      "DOI": "10.1038/clpt.2014.48",
      "author": "WL Baker",
      "doi-asserted-by": "publisher",
      "first-page": "17",
      "journal-title": "Clin Pharmacol Ther",
      "key": "BFejhg2016114_CR55",
      "unstructured": "Baker WL, Chamberlin KW : New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? Clin Pharmacol Ther 2014; 96: 17–19.",
      "volume": "96",
      "year": "2014"
    }
  ],
  "reference-count": 55,
  "references-count": 55,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/ejhg2016114"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Role of pharmacogenetics in public health and clinical health care: a SWOT analysis"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "24"
}